WO2013020624A1 - Extracts of tradescantia virginiana - Google Patents

Abstract

The present invention relates to an extract of plant parts of Tradescantia virginiana, to a method for the production thereof, and to the use thereof in cosmetic and dermatological preparations. The invention further relates to preparations containing an extract of plant parts of Tradescantia virginiana, and to a method for the production thereof.

Description

 Extracts of Tradescantia virginiana

The present invention relates to an extract of plant parts of Tradescantia virginiana, a process for its preparation, and its use in cosmetic and dermatological preparations. The invention further relates to preparations containing an extract of plant parts of Tradescantia virginiana, and to a process for their preparation. Skin and hair color are dependent on the content, size, distribution and type of the nitrogen-containing, dark dye melanin, which is produced in the melanocyte-capable cells (melanocytes).

Starting with tyrosine and using various melanocyte-specific enzymes, e.g. Tyrosinase or tyrosinase-related proteins, melanin is synthesized within the melanocytes.

 Subsequently, the melanin is transferred to the keratinocytes in the form of so-called melanosomes.

Although the melanin in the skin is a suitable protection against UV radiation, darker or over-pigmented skin may

 Influence beauty and lead to serious aesthetic problems. Hyperpigmented areas of skin or lesions contain melasma (also called chloasma), i. irregularly shaped yellowish-brown spots. In general, one differentiates between pigment spots between freckles (ephelides), age spots (lentigines), so-called age warts

 (Verrucae seborrhoicea) and hyperpigmentation (e.g., Chloasma or Melasma). Freckles are especially prone to skin type I, i. with very light skin and reddish hair.

Hyperpigmentation (chloasma), on the other hand, is common in those women who routinely deliver estrogen to their bodies. Very often the sun plays an important role. You can prevent it mainly by regular sunscreen with a high SPF. In order to remove unsightly pigment spots, different ones are available

Options such as laser, Dermabrasio or other electrosurgical procedures and so-called bleaching creams on. The latter alternative has the advantage that it is much cheaper for the patient than the electrosurgical procedures. In addition, the application is easier and more enjoyable.

A large number of skin-whitening compounds for the treatment of pigmentation marks are available on the market. Among others, these are compounds such as e.g. Hydroquinone (1,4-dihydroxybenzene), kojic acid, arbutin, aloesin, niacinamide, vitamin C or rucinol, which suppress the production of melanin in the skin. Also

Plant extracts such as e.g. from Morus alba or Phyllanthus emblica find, especially in the Southeast Asian region, application to brighten the Hautteint.

 This can be done using different mechanisms.

However, most of the skin lightening agents delay the conversion of tyrosine into melanin by blocking the enzyme tyrosinase. However, these known compounds have a number of disadvantages, such as e.g. low depigmentation efficiency, side effects such as skin irritation or skin exfoliation, cell damage, low

 Skin penetration or low durability or stability of

 Formulations. Therefore, a need for new safe

 Skin whitening with higher effectiveness and good

 Formulation properties available.

In addition, the trend away from the noble paleness to the "healthy, sporty browned skin" for years still unbroken.To achieve a tanned complexion, people expose their skin to the sun's rays, as this pigmentation by a

Melaninbildung causes. However, the UV radiation of sunlight has also a damaging effect on the skin. In addition to the acute

Injury (sunburn) causes long-term damage from excessive exposure to light from the UVB range (wavelength 280-320 nm), such as an increased risk of developing skin cancer. Excessive exposure to UVB and UVA radiation (wavelength: 320-400 nm) produces highly reactive radical species, which also increase

Continuing to increase irradiation and as a result, it comes to wrinkling and skin aging.

Natural protection against the negative effects of solar radiation is provided by the tanning (pigmentation) of the skin. The epidermis contains in its lowest layer, the basal layer, in addition to the basal cells, individual pigment-forming cells, the melanocytes. UV light in these cells stimulates the production of melanin, which is transported to the keratinocytes (horny cells) where it becomes visible as a brown skin color.

Melanin protects the cell nuclei from further irradiation and the resulting negative effects on the cell DNA.

Depending on the chemical composition of the biochemically formed

Pigments are distinguished between the brownish-black eumelanin and the reddish-yellow pheomelanin. The observed skin tone is determined by the ratio of these two types of melanin.

This formation of pigment originating from the amino acid tyrosine is predominantly initiated by UVB radiation and called "indirect

 Their development takes place over several days, the sun tan thus obtained persists for several weeks, in the case of "direct pigmentation", which starts with the sun's rays

predominantly colorless melanin precursors are oxidized by UVA radiation to dark-colored melanin. Since this oxidation is reversible, it leads to a short-lasting tanning of the skin. An artificial tanning of the skin can be produced externally with the help of make-up and orally by taking carotenoids.

Far more popular, however, is the artificial tanning of the skin, which can be achieved by applying so-called self-tanner.

Many of these compounds have as a chemical structural feature keto or aldehyde groups in the vicinity of alcohol functions and belong predominantly to the substance class of sugars. Particularly commonly used self-tanning substances are 1,3-dihydroxyacetone (DHA), used in an amount of 700 t / a, and erythrulose.

Classic self-tanning agents can be reacted with the proteins and amino acids of the horny layer of the skin in the sense of a Maillard reaction or via a Michael addition, whereby polymers which give the skin a brownish hue emerge via a not yet fully elucidated reaction pathway. This reaction is completed in about 4 to 6 hours. The tan thus obtained is not washable and is removed only with the normal Hautabschuppung.

However, these color products themselves have no UV-absorbing properties, so when exposed to the sun, an additional

Sunscreen (clothing, hat, UV filter) is required.

 In contrast to "tanned" skin, the tanned skin is not protected against sunburn.

There is therefore a need for dermatologically acceptable

 Skin-staining substances which are suitable for use in cosmetic and / or dermatological preparations or medical products and which enhance the natural tanning of the skin by increasing the synthesis of melanin and at the same time better skin protection or

Sun protection, especially against UVB radiation allow. It is an object of the present invention to provide novel agents that affect the appearance and hue of the skin by acting as a self-tanning or skin whitening agent.

Surprisingly, it has now been found that extracts from

Plant parts of Tradescantia virginiana depending on the selected

Extraction conditions both have a high skin lightening effect and can act as a self-tanning agent.

For the purposes of the invention, the term self-tanning active is used synonymously with self-tanning substance, self-tanner or self-tanning substance. Tradescantia virginiana is a herbaceous plant that is planted in gardens for ornamental purposes. It is also used in bioassays to test the presence of ionizing radiation, which causes its stamens to turn red.

 For the purposes of the present invention, plant hybrids of Tradescantia virginiana are also included, i. Plants derived from a cross of Tradescantia virginiana with another species or subspecies of the genus Tradescantia.

 The use of extracts of Tradescantia virginiana in

cosmetic or dermatological preparations is not known in the prior art; for topical applications, only the

 Use of the species Tradescantia spathacea described:

JP 2009040753 describes skin-repairing compositions containing plant extracts of Tradescantia spathacea. In EP 1009378 the use of plant extracts of Rhoeo discolor (= Tradescantia spathacea) in cosmetic and

disclosed pharmaceutical preparations. DE 102007042009 A1 describes pharmaceutical formulations which, inter alia, can also be used for the treatment of skin diseases and contain an extract of Tradescantia spathacea.

A first subject of the present invention is therefore an extract of plant parts of Tradescantia virginiana.

 In principle, all above-ground parts of the plant can be used for the extract. Plant parts preferably used for extraction are the leaves or flowers or mixtures thereof, more preferably the leaves are used.

The plant extract of Tradescantia virginiana can be prepared by methods known to those skilled in the art. A plant extract which is particularly suitable for the use according to the invention is obtainable by a) extraction of the plant parts of Tradescantia virginiana with the aid of a solvent and, optionally, b) removal of the solvent.

Accordingly, a process for producing an extract from plant parts of Tradescantia virginiana is also the subject of the invention, comprising the steps of a) extraction of the plant parts of Tradescantia virginiana with the aid of a solvent and, optionally, b) removal of the solvent.

The plant parts can be used directly for the extraction according to step a). Typically, however, the plant parts are first dried and crushed.

The drying can be carried out, for example, in air or preferably in a drying oven at elevated temperature, preferably between 30 and 50 ° C, more preferably at about 40 ° C. In addition, the drying can also be carried out under reduced pressure.

The crushing can be done by common methods, for example by using cutting tools such as knives or scissors, or by using a blender. For larger quantities, mills such as hammer mills can be used.

Subsequently, the plant parts are extracted. The extraction is carried out by methods known to those skilled in the art. For this, the plant parts are typically mixed with a solvent.

Preference is given to using a solvent selected from water, organic solvents or mixtures thereof. Examples of organic solvents are methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, acetone or ethyl acetate.

 Solvent mixtures of water and organic solvents preferably contain 0-90% by volume of water, particularly preferably 30-70% by volume of water.

In a preferred embodiment of the present invention, the solvent is selected from water or alcohol. In a particularly preferred embodiment, an alcohol, in particular ethanol, is used as solvent. In a further preferred embodiment, water is used as the solvent.

The extraction is typically carried out at temperatures between 20 and 90 ° C, preferably between 50 and 90 ° C, more preferably at the boiling point of the solvent or solvent mixture. This means that when using water as a solvent the

Extraction is particularly preferably carried out at about 00 ° C, while the extraction is particularly preferably carried out at about 78 ° C when using ethanol as a solvent. In optional step b), the solvent is removed. This is typically done by filtration.

 Preferably, the method also comprises step b).

The resulting extract may optionally be further purified. All methods familiar to the person skilled in the art can be used for this purpose, for example chromatographic methods such as solid phase adsorption with subsequent stepwise desorption by means of suitable solvents. The chromatography can also be carried out in countercurrent. Concentration and enrichment can also take place by means of supercritical gases or ionic liquids. It is also possible by liquid / liquid extraction to deplete unwanted

To achieve ingredients. For this purpose, the dry extract obtained is usually taken up in a little water and extracted with a further solvent, such as heptane. Unless it is a

This water extract can also be purified as a concentrated crude extract directly (without further addition of water) with another solvent in a liquid / liquid extraction. Even by changing the solvent with subsequent filtration unwanted components can be removed.

Optionally, the extract obtained can then be concentrated and / or dried in a step c).

This can be done using methods common to the person skilled in the art. The

Concentration takes place, for example, using a

Rotary evaporator or a falling film evaporator, and can also be done under reduced pressure. The extract can be dried, for example, by means of spray drying or freeze drying. The extract is preferably dried completely to constant weight. Another object of the present invention is the use of an extract from plant parts of Tradescantia virginiana, as described above, in cosmetic or dermatological preparations. In a preferred embodiment, the use for

Lightening of the skin.

According to the invention, the extracts of plant parts of

Tradescantia virginiana with good compatibility at the same time valuable cosmetic and / or pharmacological properties by the

 Skin lightening associated with a relative melanin content of less than 90%, preferably less than 80%, more preferably less than 70%. A particularly preferred embodiment of the present invention is the use of an extract from plant parts of Tradescantia virginiana for the inhibition of melanin synthesis, for the prophylaxis, treatment and / or follow-up of pigmentary disorders of the skin. Inhibition of melanin synthesis can be accomplished, for example, by regulation of the transcription or activity of tyrosinase (e.g., inhibition or degradation of tyrosinase), TRP-1 (tyrosinase related protein), TRP-2 (tyrosinase related protein-2), and / or peroxidase. This is also possible in vitro. The term "inhibition" refers to any reduction in activity based on the action of the specific extract of the invention and by recognition, binding and blocking of the activity

Target molecules is enabled.

The aforementioned use of the extract can be done in in vitro or in vivo models. The susceptibility of a particular cell to treatment with the extract can be determined by testing in vitro. Typically, a culture of the cell with the Extract of the invention is incubated at various concentrations for a period of time sufficient to allow the active agents to inhibit the synthesis of melanin, usually between about one hour and one week. Cultured cells from a biopsy sample can be used for testing in vitro. The amount of post-treatment melanin in the cells is then determined. The use in vitro is carried out in particular on samples of

Mammalian species that suffer from skin pigmentation disorders. The host or patient may be of any mammalian species, e.g. B. one

Primate species, especially humans, but also rodents

(including mice, rats and hamsters), rabbits, horses, cattle, dogs, cats, etc.

The in vivo dose of the extract is advantageously matched to the susceptibility of the tyrosinase and / or severity of the patient's pigmentation disorder with respect to the in vitro data, thereby significantly increasing efficacy. Typically, a cosmetic dose will be sufficient to significantly reduce the undesirable amount of melanin in the target tissue while maintaining and ultimately improving the patient's quality of life.

Use will generally continue until there is a significant reduction in tyrosinase activity and / or melanin production, e.g. at least about 10% reduction in melanin content and can be continued until essentially no undesirable

 Overproduction of melanin is more demonstrated. It is understood that a skin lightening a repeated or lasting

 Treatment, since after discontinuation of the preparations, the normal

 Melaninsyntheserate is resumed.

According to the invention, extracts of plant parts of Tradescantia virginiana are furthermore for use in prophylaxis, treatment and / or follow-up of pigment disorders which

For example, selected from the group of hyperpigmentation, freckles, age spots and sunspots. It is believed that the high skin whitening activity of

extracts according to the invention, without being bound to this theory, is due to a combination of different active components in the extracts. In addition to the above options for

Inhibition of melanin synthesis (e.g., by regulation of transcription or activity of tyrosinase, TRP-1, TRP-2, and / or peroxidase) can generally also be achieved by regulation of skin lightening

Uptake and distribution of melanosomes in the

Receiver keratinocytes, the breakdown of melanin or melanosomes or the detachment of pigmented keratinocytes happen.

The skin-lightening effect of the extract is particularly good when it is prepared by the method described above and in particular according to its preferred embodiments.

 For skin lightening, especially water extracts from plant parts of Tradescantia virginiana are suitable, ie extracts in which

 Production in step a) of the process according to the invention, as described above, water is used as solvent.

In a further preferred embodiment, the use of the extract according to the invention takes place as a self-tanning agent.

Extracts from plant parts of Tradescantia virginiana can therefore also have very good browning properties.

According to the invention, this is preferably the use for increasing melanin synthesis, improving melanin transport and / or improving the distribution of melanin in suprabasal

Layers.

The extracts according to the invention increase the melanin synthesis and improve the melanin transport from the melanocytes to the

Keratinocytes. This affects the color of the skin and causes a tanning effect. The extracts according to the invention act as biological self-tanning agents, i. as a melanogenesis promoter or

Propigmentation agents that promote the natural tanning of the skin.

Again, it is believed that the high tanning activity of

extracts according to the invention, without being bound to this theory, is due to a combination of different active components in the extracts.

 The tanning action of the extract is particularly good when used according to the method described above, and in particular according to their

preferred embodiments is produced.

Alcoholic extracts from plant parts of Tradescantia virginiana are particularly suitable as self-tanning agents, ie extracts in the preparation of which in step a) of the process according to the invention, as described above, an alcohol is used as solvent.

This is particularly preferably ethanol.

The use of extracts of plant parts of Tradescantia virginiana for skin lightening, as well as for self-tanning has the advantage that even at very low concentration, a strong effect can be achieved. They advantageously show a high and long-lasting activity with regard to their action as skin-whitening or skin-tanning

Agents.

 In addition, the extracts are also characterized by a high

Application security and good formability. So they are easy to incorporate into preparations and have increased stability in the Preparations. The preparation of the extracts is very

Environmentally friendly, since only small amounts of solvent must be used and no other chemicals are necessary. The use of the extracts of plant parts of Tradescantia virginiana can therefore cosmetic or pharmaceutical,

especially dermatological, nature. It is preferably a cosmetic use, more preferably a non-therapeutic cosmetic use.

Another object of the present invention is a preparation containing an extract of plant parts of Tradescantia virginiana as described above. The preparations are usually topically applicable preparations, for example cosmetic or cosmetic preparations

pharmaceutical (dermatological) formulations or medical devices. The preparations in this case contain a cosmetically or dermatologically suitable carrier and, depending on the desired

Property profile optional further suitable ingredients. In the case of pharmaceutical preparations, the preparations in this case contain a pharmaceutically acceptable carrier and optionally further pharmaceutical active ingredients. It is preferably a cosmetic or pharmaceutical preparation; most preferably it is a cosmetic preparation.

For the purposes of the present invention, the term "preparation" is synonymous with the term "agent", "composition" or "formulation" used. Topically applicable means according to the invention that the preparation is applied externally and locally, ie that the preparation must be suitable in order to be applied to the skin, for example. The preparations may contain the necessary or optional

Components include, contain, consist essentially of, or consist of. Any compounds or components which may be used in the compositions are either known and commercially available or may be synthesized by known methods.

The preparations according to the invention preferably contain from 0.01 to 99% by weight of the extract of plant parts of Tradescantia virginiana, based on the total weight of the preparation. Preference is given to using an amount of from 0.05 to 30% by weight, more preferably from 0.1 to 10% by weight. The expert does not have any difficulties in selecting the quantities according to the intended effect of the preparation.

The preparations according to the invention may contain further ingredients.

Preferred preparations according to the invention may contain at least one self-tanning substance as further ingredient. This can be either a self-tanner, which reacts with the amino acids of the skin in the sense of a Maillard reaction or via a Michael addition, as well as a so-called melanogenesis promoter or Propigmentierungswirkstoff that promotes the natural tanning of the skin. Advantageous self-tanning substances which can be used include: 1,3-dihydroxyacetone, glycerolaldehyde,

Hydroxymethylglyoxal, γ-dialdehyde, erythrulose, 6-aldo-D-fructose, ninhydrin, 5-hydroxy-1,4-naphthoquinone (juglone) or 2-hydroxy-1, 4- naphtochinon (Lawson). Very particular preference is 1, 3-dihydroxyacetone, erythrulose or a combination thereof.

In principle, propigmentation substances can be all active ingredients known to the person skilled in the art. Examples include glycyrrhetinic acid, melanocyte-stimulating hormone (alpha-MSH), peptide analogues, thymidine

Dinucleotides, L-tyrosine and its esters or bicyclic monoterpene diols (described in Brown et al., Photochemistry and Photobiology B: Biology 63 (2001) 148-161). Preferably, the at least one self-tanning substance is in the

 Preparation in an amount of 0.01 to 20 wt .-%, particularly preferably in an amount of 0.5 to 15 wt .-% and most preferably in an amount of 1 to 8 wt .-%, based on the total amount the preparation included.

Preparations with self-tanning properties, especially those containing dihydroxyacetone, tend to be used on the

Human skin to malodors, which are probably caused by degradation products of the dihydroxyacetone itself or by products of side reactions and which are perceived by the users sometimes as unpleasant. It has been found that these off-odors are avoided when using formaldehyde scavengers and / or flavonoids. Therefore, the preparation according to the invention can also

Formaldehydfänger and possibly flavonoids to improve the odor.

If the extract according to the invention already has a skin-tanning effect on its own (for example, if it is an alcoholic extract), the preparation according to the invention which has a skin tanning effect

Self-tanning substance and the extract of plant parts of

Tradescantia virginiana combined, opposite one Self-tanning product without addition of the extract according to the invention has the following advantages:

 - Extension of the tanning reaction due to indirect

Tanning reaction (UV-free tanning extension),

 - strengthening of the tanning reaction,

 - avoidance of uneven browning due to clumsy application,

 - the tanning achieved is close to the natural tanning,

 - Improved protection against UV radiation.

If the extract according to the invention itself has a skin-lightening effect (for example a water extract), a corresponding preparation which combines the extract and a self-tanning substance generally has a contrast-reducing effect and makes it possible to achieve an even skin tone. Accordingly, the extracts of plant parts of Tradescantia virginiana can also be used according to the invention in combination with self-tanning substances for the purpose of reducing the contrast and achieving an even skin tone. A contrast reducing agent is a substance that reduces uneven skin coloration by reducing the contrast between stronger and less-colored areas of the skin. In this case, such an uneven skin coloration can be caused by an uneven pigmentation and / or a different distribution of the cornea. Uneven pigmentation is by no means uncommon in the population and is due to a different degree of melanin production of the melanocytes or an irregular distribution of the melanocytes in the skin. The union of tanning mixtures based on the Maillard reaction or Michael addition with

melanogenesis inhibiting substances already causes

hyperpigmented skin areas lose their high melanin concentrations and the hue generated by the colorant on the skin surface is widely spread. A contrast reduction can be achieved in particular by preparations in which an extract of plant parts of Tradescantia virginiana with a self-tanning substance, preferably

Dihydroxyacetone (DHA) and derivatives derived therefrom, containing DHA rapid, DHA plus or erythrulose, or a mixture of

Self-tanning substances, preferably containing DHA, DHA rapid, DHA plus and / or erythrulose. As advantageous

Self-tanning agents in a mixture or preparation containing dihydroxyacetone may be used inter alia: glycerolaldehyde, hydroxymethylglyoxal, γ-dialdehyde, 6-aldo-D-fructose, ninhydrin, 5-hydroxy-1,4-naphthoquinone (juglone) or 2-hydroxy-1 , 4-naphthoquinone (Lawson) or a mixture of said compounds. Erythrulose is particularly preferably used in the mixture containing dihydroxyacetone. Very particular preference is given to using dihydroxyacetone or a derivative derived therefrom without further self-tanning substances.

In addition to the extract of Tradescantia virginiana, the preparations according to the invention may also contain at least one active substance or extract with a skin-lightening activity. If the extract according to the invention itself has a skin-lightening effect, the addition of a further skin-lightening active substance can enhance the skin-healing effect. Skin-lightening active ingredients (or synonymously depigmenting agents) which can be used in the preparations according to the invention can, in principle, be all active ingredients known to the person skilled in the art. Commercially available melanogenesis inhibitors, such as, for example, ascorbic acid and its derivatives, aloesin, niacinamide, emblica, elagic acid, licorice extract, mulberry tree extract, kojic acid, licorice root extract, rucinol, hydroquinone and its derivatives, azelaic acid, arbutin, magnesium ascorbyl phosphate, pantothenic acid and their derivatives or salts, Glucosamine and its derivatives, mercaptoamines, hinokitol, tocopherols, ubiquinones, glabridin, 4-hydroxyanisole, 4-tert-butylphenol, resveratrol, 4-S-cystaminylphenol, glutathione, lactic acid or the like. Preferred examples of compounds having skin-lightening activity are

Hydroquinone, niacinamide, ascorbic acid and physiologically acceptable salts thereof, kojic acid, arbutin, aloesin, azelaic acid, elagic acid or rucinol. Preferred examples of extracts with skin-lightening activity are licorice extract, mulberry extract or emblica. The preparations according to the invention can also be used in addition to

Extracts according to the invention also additionally contain at least one UV filter.

Organic UV filters, called hydrophilic or lipophilic

Sunscreen filters are effective in the UVA range and / or UVB range and / or IR and / or VIS range (absorber). These substances can be obtained, in particular, from cinnamic acid derivatives, salicylic acid derivatives,

Camphor derivatives, triazine derivatives, β, β-diphenylacrylate derivatives, p-aminobenzoic acid derivatives and polymeric filters and silicone filters described in application WO-93/04665.

 Further examples of organic filters are given in the patent application EP-A 0 487 404. In the following, the named UV filters are usually named according to the INCI nomenclature. In particular suitable for a combination are:

para-aminobenzoic acid and its derivatives: PABA, ethyl PABA, ethyl dihydroxypropyl PABA, ethylhexyl dimethyl PABA, e.g. B. sold under the name "Escalol 507" from the company. ISP, glyceryl PABA, PEG-25 PABA, z. B. sold under the name "Uvinul P25" from the company. BASF.

Salicylates: Homosalates are sold under the name "Eusolex HMS" by Merck; Ethyl hexyl salicylates, e.g. B. sold under the name "Neo Heliopan OS "from Symrise, Dipropylene glycol salicylate, for example sold under the name" Dipsal "by the company Scher, TEA salicylate, for example sold under the name" Neo Heliopan TS "by the company. Symrise .β, β-diphenylacrylate derivatives: octocrylenes, for example sold under the

Name "Eusolex® OCR" from Merck "," Uvinul N539 "from BASF, Etocrylene, z. B. sold under the name "Uvinul N35" from BASF. Benzophenone Derivatives: Benzophenone-1, e.g. B. sold under the

Name "Uvinul 400"; Benzophenone-2, e.g. Sold under the name "Uvinul D50"; Benzophenone-3 or oxybenzone, e.g. Sold under the name "Uvinul M40"; benzophenone-4, e.g. Sold under the name "Uvinul MS40"; Benzophenone-9, e.g. B. sold under the

Name "Uvinul DS-49" from BASF, Benzophenone-5,

 Benzophenone-6, e.g. B. marketed under the name "Helisorb 1" by the company. Norquay, Benzophenone-8, z. B. sold under the name

"Spectra-Sorb UV-24" from American Cyanamid, benzophenone-12 n-hexyl 2- (4-diethylamino-2-hydroxybenzoyl) benzoate or 2-hydroxy-4-methoxybenzophenone, sold by Merck, Darmstadt under the name Eusolex® 4360.

Benzylidene camphor derivatives: 3-benzylidenecamphor, e.g. Sold under the name "Mexoryl SD" from the company. Chimex, 4-Methylbenzylidenecamphor, z. Sold under the name "Eusolex

6300 "from Merck, Benzylidenecamphorsulfonsäure, for example, sold under the name" Mexoryl SL "from the company Chimex, Camphor

benzalkonium methosulfates, e.g. Sold under the name "Mexoryl SO" from the company. Chimex, Terephthalylidenedicamphorsulfonsäure, z. Sold under the name "Mexoryl SX" by Chimex,

Polyacrylamidomethylbenzylidenecamphor sold under the name "Mexoryl SW" from Chimex. Phenylbenzimidazole derivatives: phenylbenzimidazole fatty acid, e.g. B.

sold under the name "Eusolex 232" by the company Merck, disodium phenyl dibenzimidazole tetrasulfonate, z. B. marketed under the name "Neo Heliopan AP" by Fa. Symrise.

Phenylbenzotriazole derivatives: Drometrizole trisiloxanes, e.g. B. marketed under the name "Silatrizole" by the company. Rhodia Chimie,

Methylenebis (benzotriazolyl) tetramethylbutylphenol in solid form, e.g. B. marketed under the name "MIXXIM BB / 100" from the company. Fairmount Chemical, or in micronized form as an aqueous dispersion, eg. B.

sold under the name "Tinosorb M" from BASF.

Triazine derivatives: ethylhexyltriazone, e.g. B. sold under the name "Uvinul T150" from the company. BASF, Diethylhexylbutamidotriazone, z. B.

sold under the name "Uvasorb HEB" from the company Sigma 3V, 2,4,6-tris (diisobutyl 4'-aminobenzalmalonate) -s-triazines or 2,4,6-tris (biphenyl) -1,3, 5-triazines sold as Tinosorb A2B by BASF, 2,2 '- [6- (4-methoxyphenyl) -1, 3,5-triazine-2,4-diyl] bis [5- (2-ethylhexyl) oxy] - phenol, sold as Tinosorb S by BASF, N2, N4-bis [4- [5- (1, 1-dimethylpropyl) -2-benzoxazolyl] phenyl] -N6- (2-ethylhexyl) -1, 3,5-triazine -2,4,6-triamine sold as Uvasorb K 2A from Sigma 3V.

Anthraniline derivatives: menthyl anthranilate, e.g. B. sold under the

Name "Neo Heliopan MA" from the company Symrise.

Imidazole derivatives: ethylhexyldimethoxybenzylidenedioxoimidazoline

Propionate. Benzalmalonate Derivatives: Polyorganosiloxanes containing functional benzalmalonate groups, such as polysilicone-15, z. Sold under the name "Parsol SLX" by Hoffmann LaRoche. 4,4-Diarylbutadiene Derivatives: 1,1-Dicarboxy (2,2'-dimethylpropyl) -4,4-diphenylbutadiene. Benzoxazole derivatives: 2,4-bis [5- (1-dimethylpropyl) benzoxazol-2-yl (4-phenyl) imino] -6- (2-ethylhexyl) imino-1,3,5-triazines, e.g. B. sold under the name Uvasorb K2A from the company. Sigma 3V and mixtures containing this. Pi erazine derivatives such as the compound

or the UV filters of the following structures

or

It is also possible to use UV filters based on polysiloxane copolymers having a random distribution according to the following formula, where e.g. a = 1 2; b = 58 and c = 2.8 are:

The compounds listed are only examples

specific. Of course, other UV filters can be used.

Suitable organic UV-protective substances are preferably to be selected from the following list: ethylhexyl salicylate,

Phenylbenzimidazolesulfonic acid, benzophenone-3, benzophenone-4, benzophenone-5, n-hexyl 2- (4-diethylamino-2-hydroxybenzoyl) benzoate, 4-methylbenzylidenecamphor, terephthalylidenedicamphorsulfonic acid, disodium phenyldibenzimidazoletetrasulfonate,

Methylenebis (benzotriazolyl) tetramethylbutylphenol, ethylhexyl triazone, diethylhexyl butamido triazone, drometrizole trisiloxane, polysilicone-15, 1,1-dicarboxy (2,2'-dimethylpropyl) -4,4-diphenylbutadiene, 2,4-bis [5-1 (dimethylpropyl) benzoxazol-2-yl (4-phenyl) imino] -6- (2- ethylhexyl) imino-1,3,5-triazines and mixtures thereof. These organic UV filters are usually incorporated in formulations in an amount of from 0.01% to 20% by weight, preferably from 1% to 10% by weight.

The preparations may contain, in addition to the extracts according to the invention and the optionally organic UV filters, as described above, further inorganic UV filters, so-called particulate UV filters.

These combinations with particulate UV filters are possible both as a powder and as a dispersion or paste of the following types.

In this case, both those from the group of titanium dioxides such.

coated titanium dioxide (e.g., Eusolex® T-2000, Eusolex® T-AQUA,

Eusolex® T-AVO, Eusolex® T-OLEO), zinc oxides (e.g., Sachtotec®),

Iron oxides or else cerium oxides and / or zirconium oxides are preferred.

Furthermore, combinations with pigmentary titanium dioxide or

Zinc oxide is possible, the particle size of these pigments being greater than or equal to 200 nm, for example Hombitan® FG or Hombitan® FF-Pharma.

It may further be preferred if the preparations contain inorganic UV filters which are prepared by customary methods, such as, for example, in US Pat

Cosmetics & Toiletries, February 1990, Vol. 105, pp. 53 64 described, were treated. In this case, one or more of the following aftertreatment components may be selected: amino acids,

Beeswax, fatty acids, fatty acid alcohols, anionic surfactants, lecithin, phospholipids, sodium, potassium, zinc, iron or aluminum salts of Fatty acids, polyethylenes, silicones, proteins (especially collagen or elastin), alkanolamines, silica, alumina, other metal oxides, phosphates, such as sodium hexametaphosphate or glycerol.

Preferably used particulate UV filters are:

untreated titanium dioxides, e.g. the products Microtitanium Dioxide MT 500 B from Tayca; Titanium Dioxide P25 from Degussa,

 Post-treated micronized titanium dioxides with alumina and

 Silica post-treatment such as e.g. the product "Microtitanium Dioxide MT 100 SA of Tayca; or the product "Tioveil Fin" from Uniqema,

 Aftertreated micronised titanium dioxides with alumina and / or aluminum stearates / laurate aftertreatment such as e.g. Microtitanium Dioxide MT 100 T from Tayca, Eusolex T-2000 from Merck,

Post-treated micronized titanium dioxides with iron oxide and / or

 Iron stearates aftertreatment such as e.g. the product "Microtitanium Dioxide MT 100 F" from Tayca,

 Aftertreated micronised titanium dioxides with silicas,

 Alumina and silicone aftertreatment such as e.g. the product "Microtitanium Dioxide MT 00 SAS", the company Tayca,

 - Post-treated micronized titanium dioxides with

 Sodium hexameta-phosphates, e.g. the product "Microtitanium

 Dioxide MT 150 W "from the company Tayca.

The treated micronized titanium dioxides used for combination may also be post-treated with:

- octyltrimethoxysilanes; such as. the product Tego Sun T 805 of the Fa.

 Degussa,

- silica; such as the product Parsol TX from DSM, Alumina and stearic acid; such as the product UV titanium M160 Fa. Sachtleben,

 - aluminum and glycerin; such as. the product UV titanium of the Fa.

 Sachtleben

 Aluminum and silicone oils, e.g. the product UV titanium M262 of the Fa.

 Sachtleben,

 Sodium hexamethaphosphate and polyvinylpyrrolidone,

 Polydimethylsiloxanes, e.g. the product 70250 Cardre UF Ti02SI3 "from the company Cardre,

 Polydimethylhydrogensiloxanes, e.g. the product Microtitanium

 Dioxide USP Grade Hydrophobia "from Color Techniques.

Furthermore, the combination with the following products may also be advantageous:

- Untreated zinc oxides such. B. the product Z-Cote Fa. BASF

 (Sunsmart), Nanox of the company Elementis

 Aftertreated zinc oxides such as the following products:

 • "Zinc Oxide CS-5" from Toshibi (ZnO aftertreated with

 polymethylhydrogenosiloxane)

 • Nanogard Zinc Oxide FN from Nanophase Technologies

• "SPD-Z1" from Shin-Etsu (ZnO aftertreated with a

 Silicone-grafted acrylic polymer dispersed in cyclodimethylsiloxanes

 "Escalol Z100" from ISP (alumina aftertreated ZnO dispersed in an ethylhexyl methoxycinnamate / PVP-hexadecenes / methicone copolymer blend)

 , Fuji ZNO-SMS-10 from Fuji Pigment (ZnO aftertreated with silica and polymethylsilsquioxane);

 Untreated cerium oxide micropigment e.g. with the name "Colloidal Cerium Oxide" from Rhone Poulenc

• Untreated and / or post-treated iron oxides with the Name Nanogar of the Fa. Arnaud.

By way of example, mixtures of various metal oxides, e.g. Titanium dioxide and cerium oxide with and without Nachbenhandlung be used, such. the product Sunveil A of the company Ikeda. In addition, mixtures of alumina, silica and

Silicon aftertreated titanium dioxide, zinc oxide mixtures such. the product UV titanium M261 from Sachtleben be used. These inorganic UV filters are usually incorporated in the formulations in an amount of from 0.1 percent by weight to 25 percent by weight, preferably from 2 percent by weight to 10 percent by weight.

By combining one or more of the compounds mentioned with UV filter action, the protective effect against harmful

Effects of UV radiation can be optimized.

All mentioned UV filters can also be used in encapsulated form. In particular, it is beneficial to use organic UV filters in

to use encapsulated form.

The capsules in preparations to be used according to the invention are preferably present in amounts which ensure that the encapsulated UV filters in the abovementioned

Weight percent ratios are present in the preparation.

In the described preparations containing the extract according to the invention, color pigments may furthermore furthermore be present, the layer structure of the pigments not being limited. Preferably, the color pigment when used from 0.5 to 5 wt .-% should be skin-colored or brownish. The selection of a corresponding

Pigments is familiar to the skilled person.

Furthermore, at least one further active ingredient can be present in the preparations according to the invention. The further active ingredient is preferably selected from the group of antioxidants, vitamins, anti-aging agents, anti-inflammatory agents, antimicrobial

Active ingredients, active ingredients for improving the moisture content of the skin (skin moistness regulators), anti-cellulite active ingredients, anti-wrinkle agents, anti-dandruff agents, anti-acne agents, deodorants and pigments, particularly preferably from the group of antioxidants, vitamins , Anti-aging agents and anti-cellulite agents, most preferably from the group of antioxidants and vitamins.

Substances that serve to maintain and / or improve the moisture content of the skin can, without this as

Restriction is to be understood, inter alia, substances that belong to the so-called natural moisturizing factors, such. 2-oxopyrrolidines 5-carboxylic acid.

The protective effect of preparations against oxidative stress or against the action of radicals can be improved if the preparations contain one or more antioxidants, wherein the skilled person has no difficulty in selecting suitable fast or delayed-acting antioxidants.

There are many known and proven substances in the literature that can be used as antioxidants, e.g. Amino acids (e.g.

Glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles, (eg urocaninic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (eg anserine), carotenoids, carotenes (eg a- Carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid),

Aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl , γ-linoleyl, cholesteryl and glyceryl esters) and their salts,

Dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (for example buthionine sulfoximines,

Homocysteine sulfoximine, buthionine sulfone, penta-, hexa-,

 Heptathionine sulfoximine) in very low tolerated dosages (e.g., pmol to pmol / kg), further (metal) chelators (e.g., α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g.

Citric acid, lactic acid, malic acid), humic acid, bile acid,

Gaillenextrakte, Bilirubin, Biliverdin, EDTA, EGTA, Pentasodium

ethylenediaminetetramethylene phosphonate and its derivatives, unsaturated fatty acids and their derivatives, vitamin C and derivatives (e.g.

Ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate),

Tocopherol and derivatives (e.g., vitamin E acetate), vitamin A and derivatives (e.g., vitamin A palmitate), and benzoic acid coniferyl benzoate, rutinic acid and derivatives thereof, α-glycosyl rutin, ferulic acid,

 Furfurylidenglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordohydroguajaretic acid, trihydroxybutyrophenone, quercitin, uric acid and its derivatives, mannose and its derivatives, zinc and its

Derivatives (eg ZnO, ZnS0 ₄ ), selenium and its derivatives (eg

 Selenethethionine), silibens and their derivatives (e.g., stilbene oxide, trans-stilbene oxide).

Suitable antioxidants are also compounds of the formulas A or B.

wherein

R can be selected from the group -C (O) CH ₃ , -CO ₂ R ³ , -C (O) NH ₂ and -C (O) N (R) ₂

X is O or NH,

R ^{2 is} linear or branched alkyl having 1 to 30 C atoms,

R ^{3 is} linear or branched alkyl having 1 to 20 C atoms,

R ⁴ each independently of one another are H or linear or branched alkyl having 1 to 8 C atoms,

R ⁵ H, linear or branched alkyl having 1 to 8 carbon atoms or

 linear or branched alkoxy having 1 to 8 C atoms and

R ⁶ denotes linear or branched alkyl having 1 to 8 C atoms, preferably derivatives of 2- (4-hydroxy-3,5-dimethoxybenzylidene) malonic acid and / or 2- (4-hydroxy-3,5-dimethoxybenzyl) - malonic acid, more preferably 2- (4-hydroxy-3,5-dimethoxybenzylidene) -malonic acid bis (2-ethylhexyl) ester (eg Oxynex® ST Liquid) and / or 2- (4-hydroxy-3,5-dimethoxybenzyl ) -malonic acid bis (2-ethylhexyl) ester (eg RonaCare® AP).

Mixtures of antioxidants are also suitable for use in the formulations of the invention. Known and purchasable Mixtures are, for example, mixtures containing as active

Ingredients lecithin, L - (+) - ascorbyl palmitate and citric acid, natural tocopherols, L - (+) - ascorbyl palmitate, L - (+) - ascorbic acid and

Citric acid (e.g., Oxynex® K LIQUID), tocopherol extracts

natural sources, L - (+) - ascorbyl palmitate, L - (+) - ascorbic acid and citric acid (eg Oxynex® L LIQUID), DL-a-tocopherol, L (+) - ascorbyl palmitate, citric acid and lecithin (eg Oxynex® LM) or butylhydroxytoluene (BHT), L - (+) - ascorbyl palmitate and citric acid (eg Oxynex® 2004). Such antioxidants are used in the

Compositions according to the invention usually in amounts of

0.1 to 20 wt .-%, preferably used in amounts of 0.1 to 10 wt .-%.

Among the phenols which can be used according to the invention, the polyphenols, which occur in part as natural substances, are of particular interest for applications in the pharmaceutical, cosmetic or nutritional field. For example, the flavonoids or bioflavonoids, which are mainly known as plant dyes, frequently have an antioxidant potential. With effects of the substitution pattern of mono- and

Dihydroxy flavones deal with K. Lemanska, H. Szymusiak, B.

Tyrakowska, R. Zielinski, I.M.C.M. Rietjens; Current Topics in Biophysics 2000, 24 (2), 01-108. It is observed there that dihydroxyflavones having an OH group adjacent to the keto function or OH groups in the 3'4 'or 6,7 or 7,8 position have antioxidant properties, while other mono- and dihydroxyflavones are partially non-antioxidant

Have properties.

Quercetin (cyanidanol, cyanidolone 1522, meietin,

 Sophoretine, ericin, 3,3 ', 4', 5,7-pentahydroxyflavone) as particular

effective antioxidant (e.g., CA. Rice-Evans, N.J. Miller, G.

Paganga, Trends in Plant Science 1997, 2 (4), 152-159). K. Lemanska, H. Szymusiak, B. Tyrakowska, R. Zielinski, AEMF Soffers and IMCM Rietjens (Free Radical Biology & Medicine 2001, 31 (7), 869-881 the pH dependence of the antioxidant effect of hydroxyflavones. Quercetin shows the highest activity of the investigated structures over the entire pH range. Suitable anti-aging ingredients, especially for skin care

 Preparations are preferably so-called compatible solutes. These are substances that are involved in the osmoregulation of

Plants or microorganisms are involved and can be isolated from these organisms. Under the generic term compatible solutes also the described in the German patent application DE-A-10133202 osmolytes are taken. Suitable osmolytes are, for example, the polyols, methylamine compounds and amino acids and in each case their precursors. As osmolytes are in the sense of the Germans

Patent application DE-A-10133202 especially substances from the group of polyols, such as myo-inositol, mannitol or sorbitol and / or understood one or more of the following osmolytically active substances: taurine, choline, betaine, phosphoryicholine, Glycerophosphorylcholine, glutamine, glycine , α-alanine, glutamate, aspartate, proline, and taurine. Precursors of these substances are, for example, glucose, glucose polymers, phosphatidylcholine, phosphatidylinositol, inorganic phosphates, proteins, peptides and polyamic acids. Precursors are z. B. Compounds that are converted to osmolytes by metabolic steps. Preferably according to the invention as compatible solute substances selected from the group consisting of Pyrimidincarbonsäuren (such as ectoine and hydroxyectoine), proline, betaine, glutamine, cyclic

 Diphosphoglycerate, N. acetylornithine, trimethylamine N-oxide di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1, 1-diglycerol phosphate (DGP), β-mannosylglycerate (Firoin) , ß-

Mannosylglyceramide (Firoin-A) or / and di-mannosyl-di-inositol phosphate (DMIP) or an optical isomer, derivative, for example an acid, a salt or ester of these compounds or combinations thereof.

Among the pyrimidinecarboxylic acids, in particular, ectoine ((S) -I-α-tetrahydro-Z-methyl-pyrimidinecarboxylic acid) and hydroxyectoine ((S, S) -1, 4,5,6-tetrahydro-5-hydroxy 2-methyl-4-pyrimidinecarboxylic acid) and their derivatives.

Additional can be used as anti-aging active ingredients Merck products such. 5,7-dihydroxy-2-methyl-chromone, marketed under the

 Trade names RonaCare®l_uremine, Ronacare®lsoquercetin,

Ronacare® tiliroside or Ronacare® cyclopeptide 5 can be used.

The preparations to be used may be further ingredients

Contain vitamins. Preference is given to vitamins and vitamin derivatives selected from vitamin A, vitamin A propionate, vitamin A palmitate, vitamin A acetate, retinol, vitamin B, thiamin chloride hydrochloride (vitamin Bi), riboflavin (vitamin B ₂ ), nicotinamide, Vitamin C (ascorbic acid), vitamin D, ergocalciferol (vitamin D ₂ ), vitamin E, DL-a-tocopherol, tocopherol-E-acetate, tocopherol hydrogen succinate, vitamin K _{1 t} esculin (vitamin P active ingredient), thiamine (vitamin B, Nicotinic acid (niacin),

Pyridoxine, pyridoxal, pyridoxamine, (vitamin B ₆ ), pantothenic acid, biotin, folic acid and cobalamin (vitamin B ₂ ), particularly preferably vitamin A palmitate, vitamin C and its derivatives, DL-α-tocopherol, tocopherol E acetate , Nicotinic acid, pantothenic acid and biotin. Vitamins are usually added to the flavonoid-containing premixes or preparations when applied cosmetically in the range of 0.01% to 5.0% by weight, based on the total weight. nutritional

Applications are based on the recommended vitamin requirement.

The described retinoids are also effective anti-cellulite agents. Another well-known anti-cellulite drug is caffeine. Another embodiment of the present invention relates to a pharmaceutical composition containing an extract of plant parts of Tradescantia virginiana. A "drug", "drug" as well as a "pharmaceutical

Composition "," pharmaceutical formulation "or

"Pharmaceutical preparation" here is any agent which in the prophylaxis, therapy, follow-up or treatment of

Patients can be used, at least temporarily show a pathogenic modification of the overall condition or the condition of individual parts of the patient's organism, preferably as a result of pigmentation of the skin.

To increase the protective or therapeutic effect of the compounds of the invention, pharmaceutically acceptable

 Adjuvants are added. For the purposes of the invention, any substance which makes possible an action with the extracts according to the invention enhances or modifies an "adjuvant." Known adjuvants are, for example, aluminum compounds such as aluminum hydroxide or aluminum phosphate, saponins such as QS 21, muramyl dipeptide or

 Muramyl tripeptide, proteins, e.g. Gamma interferon or TNF, MF 59, phosphatidylcholine, squalene or polyoie. Furthermore, DNA encoding a protein with adjuvant effect can be administered in parallel or in a construct.

The introduction of the pharmaceutical agent into a cell or an organism can be done according to the invention in any way. The pharmaceutical agent of the present invention may be administered orally, topically, transdermally, transmucosally, transurethally, vaginally, rectally, pulmonarily, enterally and / or parenterally, preferably topically or transdermally. The chosen mode of administration depends on the indication, the dose to be administered, the individual specific parameters, etc. In particular, the different modes of administration allow for site-specific therapy

Minimized side effects and decreased the drug dose. The dosage forms of the pharmaceutical agent are prepared with the usual solid or liquid carriers and / or diluents and the commonly used excipients according to the desired mode of administration in a suitable dosage and in a conventional manner. In principle, therefore, pharmaceutically acceptable excipients known to those skilled in the art may form part of the pharmaceutical composition of the present invention wherein the amount of excipient material combined with the active ingredient is one

Single dose, varies depending on the individual to be treated and the mode of administration. These pharmaceutically acceptable additives include salts, buffers, fillers, stabilizers, chelants, antioxidants, solvents, binders, lubricants, tablet coatings, flavors, colors, preservatives, sizing agents, and the like. Examples of such excipients are water, vegetable oils, benzyl alcohols, alkylene glycol, polyethylene glycol,

Glycerol triacetate, gelatin, carbohydrates, e.g. Lactose or starch, magnesium stearate, talc and Vaseline.

The pharmaceutical formulation may be in the form of tablet, film-coated tablet, dragee, lozenge, capsule, pill, powder, granule, syrup, juice, drops, solution, dispersion, suspension, suppository, emulsion, implant, cream, gel, ointment, paste, lotion, serum , Oil, spray, aerosol, glue, plaster or dressing. The oral dosage form used is preferably tablets, film-coated tablets, dragees, lozenges, capsules, pills, powders, granules, syrups, juices, drops, solutions, dispersions or

 Suspensions - also prepared as depot form. Furthermore, parenteral dosage forms such as e.g. Suppositories, suspensions,

Emulsions, implants or solutions to be considered, preferably oily or aqueous solutions. For topical administration, the active pharmaceutical ingredient is at least one pharmaceutical

acceptable carrier, e.g. microcrystalline cellulose, and optionally further excipients, such as e.g. Moisturizers, to be applied to the skin solid formulations, such. Creams, gels, ointments, pastes, powders or emulsions, or to skin-applied liquid formulations, e.g. Solutions, suspensions, lotions, serums, oils, sprays or aerosols formulated in a conventional manner.

Preferably, the pharmaceutical agent is for topical application. The pharmaceutical agent may also be present as a solid composition, for example in the lyophilized state, and then by addition of a dissolving agent, such as e.g. distilled water, before the

Use to be prepared. The basics of making

Lyophilisates are familiar to the skilled worker.

The concentration of the extract in the formulation may be from 0.01 to 99% by weight. It is crucial that the pharmaceutical composition comprises as active ingredient an effective amount of the extract together with the pharmaceutically acceptable excipients. The terms "effective amount" or "effective dose" are used herein

used interchangeably and denote a lot of

pharmaceutical agent having a prophylactic or therapeutically relevant effect on a disease or pathological change in the cell, tissue, organ or mammal. A "prophylactic effect" prevents the onset of a disease and includes an increase in the normal physiological function prophylaxis is particularly advisable when an individual has predispositions for the onset of the aforementioned diseases, such as a family history, a genetic defect or a recent Illness, one

"Therapeutically relevant effect" partially or completely relieves one, several or all disease symptoms or leads to the partial or complete return of one, several or all physiological or biochemical parameters associated with or causative of the disease or pathological alteration. Also, follow-up is understood as a type of therapeutic treatment when the extract is administered at certain intervals, eg to completely eliminate the symptoms of a disease. The particular dose or range of administration for the dose is large enough to achieve the desired prophylactic or therapeutic effect of inducing a biological or medical response. In general, the dose will vary with the age, constitution and gender of the patient, as well as the severity of the disease. It is understood that the specific dose, frequency and duration of administration of a variety of

Depend on factors such as the targeting and binding ability of the compounds, nutritional habits of the to be treated

Individual, mode of administration, excretion rate and combination with other medications. The individual dose can be adjusted both in relation to the primary illness and in relation to the occurrence of possible complications. The exact dose is through one

Detectable by known means and methods.

In one embodiment of the invention, in order to promote the medicinal effect, the pharmaceutical composition may also comprise one or more further active ingredients, simultaneous or sequential administration being conceivable. The therapeutic effect of the pharmaceutical composition according to the invention may be, for example, that the inhibition of the

Tyrosinase as a desired side effect certain skin brightener work better or by reducing the dose, the number of

Side effects of these drugs is reduced. The present invention also provides a process for the preparation of a preparation as hereinbefore described

in that the extract of plant parts of Tradescantia virginiana is mixed with a carrier suitable for topical applications. Optionally, the mixing can also be carried out with other auxiliaries and / or fillers. Suitable excipients and auxiliaries or fillers are described in detail in the following part.

The said constituents of the preparation can be incorporated in the usual way, by means of techniques which are well known to the person skilled in the art. The mixing can be a dissolving, emulsifying or

Dispersing the extract, as described above, in the carrier result. The cosmetic and dermatological preparations can be in various forms. So they can z. For example, a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) type or of the oil-in-water (O / W) type, a multiple emulsion, for example of the Waser-in type. Oil-in-water (W / OW) or OW / O, a gel, a solid stick, an ointment or even an aerosol. Preference is given to emulsions. O / W emulsions are particularly preferred. Emulsions, W / O emulsions and O / W emulsions are available in the usual way. For use, the cosmetic and dermatological preparations according to the invention are applied to the skin in a sufficient amount in the manner customary for cosmetics.

As an application form of the preparations to be used, e.g.

called: solutions, suspensions, emulsions, PIT emulsions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing

Cleansing preparations, oils, aerosols, patches, envelopes, bandages and Sprays, especially for external use. Further

Application forms are e.g. Sticks, shampoos and shower baths. Further, typical cosmetic applications include lipsticks, lip balms, powder, emulsion and wax make-up as well

Sunscreen, pre-sun and after-sun preparations.

Preferred excipients come from the group of preservatives, stabilizers, solubilizers, colorants, i. Pigments / dyes, emulsifiers or odor improvers.

Ointments, pastes, creams and gels may contain the usual excipients suitable for topical administration, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth,

Cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances.

Powders and sprays may contain the usual carriers, e.g.

Lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays may additionally contain the usual volatilized, liquefied propellants, e.g.

Chlorofluorocarbons, propane / butane or dimethyl ether. Also, compressed air is advantageous to use.

Solutions and emulsions may be the usual carriers such as

Solvents, solubilizers and emulsifiers, for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol, oils, in particular cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, XTend 226 (L'Oreal) , Glycerin fatty acid esters, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances. A preferred solubilizer in general is 2-isopropyl-5-methylcyclohexanecarbonyl-D-alanine methyl ester.

Suspensions may be the usual carriers such as liquid

Diluent, e.g. Water, ethanol or propylene glycol,

Suspending agent, e.g. ethoxylated isostearyl alcohols,

Polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.

Soaps may contain the usual excipients such as alkali metal salts of fatty acids, salts of fatty acid monoesters, fatty acid protein hydrolysates, isothionates, lanolin, fatty alcohol, vegetable oils, plant extracts, glycerol, sugars or mixtures of these substances.

Surfactant-containing cleaning products, the usual carriers such as salts of fatty alcohol sulfates, fatty alcohol ether sulfates,

Sulfosuccinic monoesters, fatty acid protein hydrolysates, isothionates, imidazolinium derivatives, methyltaurates, sarcosinates,

Fatty acid amide ether sulfates, alkylamido betaines, fatty alcohols,

 Fatty acid diethanolamides, vegetable and synthetic oils, lanolin derivatives, ethoxylated glycerol fatty acid esters or mixtures of these substances. Facial and body oils may contain the usual carriers such as synthetic oils such as fatty acid esters, fatty alcohols, silicone oils, natural oils such as

 Vegetable oils and oily vegetable extracts, paraffin oils, lanolin oils or mixtures of these substances. The preferred preparation forms include in particular

Emulsions, which is present as cream or milk and contain z. As the aforementioned fats, oils, waxes and other fatty substances, and water and an emulsifier, as is customary for such a type of

Preparation is used.

Further preferred embodiments provide oily lotions based on natural or synthetic oils and waxes, lanolin,

Fatty acid esters, in particular triglycerides of fatty acids, or oily alcoholic lotions based on a lower alcohol, such as ethanol, or a glycerol, such as propylene glycol, and / or a polyol, such as glycerol, and oils, waxes and fatty acid esters, such as triglycerides of fatty acids.

The preparation may also be in the form of an alcoholic gel comprising one or more lower alcohols or polyols, such as ethanol, propylene glycol or glycerin, and a thickener, such as silica. The oily alcoholic gels also contain natural or synthetic oil or wax.

The solid sticks consist of natural or synthetic waxes and oils, fatty alcohols, fatty acids, fatty acid esters, lanolin and other fatty substances.

If a preparation is formulated as an aerosol, the usual blowing agents are generally used, such as alkanes, air, nitrogen, dinitrogen monoxide, preferably alkanes or air.

The lipid phase can be selected advantageously from the following

 Group of substances:

 - mineral oils, mineral waxes

 - Oils such as triglycerides of capric or caprylic acid, also natural oils such. Castor oil;

- Fats, waxes and other natural and synthetic fats, preferably esters of fatty acids with alcohols of low C number, eg with isopropanol, propylene glycol or glycerol, or esters of

 Fatty alcohols with lower alkanoic acids or with fatty acids; Silicone oils, such as dimethylpolysiloxanes, diethylpolysiloxanes,

 Diphenylpolysiloxanes and mixed forms thereof.

The oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the context of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 C atoms and saturated and / or unsaturated,

branched and / or unbranched alcohols of a chain length of 3 to 30 C atoms, from the group of esters of aromatic carboxylic acid and saturated and / or unsaturated, branched and / or

unbranched alcohols of a chain length of 3 to 30 C atoms. Such ester oils can then be advantageously selected from the group

Isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2

Hexadecyl stearate, 2-octyl dodecyl palmitate, oleyl oleate, oleyl erucate,

Erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, eg. B. jojoba oil.

Furthermore, the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C atoms. The fatty acid triglycerides can be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, for. Olive oil, Sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.

Any mixtures of such oil and wax components are also advantageous to use in the context of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.

The aqueous phase of the preparations to be used contains

optionally advantageous alcohols, diols or polyols lower C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, Ethylenglykolmonoethy! or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether,

Diethylene glycol monomethyl or monoethyl ether and analogous products, furthermore lower C number alcohols, e.g. For example, ethanol, isopropanol, 1, 2 propanediol, glycerol, and in particular one or more thickeners, which or which can be advantageously selected from the group

Silica, aluminum silicates, polysaccharides or their derivatives, e.g. Hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageous from the group of polyacrylates, preferably a polyacrylate from the group of so-called Carbopols, for example Carbopols types 980, 981, 1382, 2984, 5984, each individually or in combination.

In particular, mixtures of the abovementioned solvents are used. For alcoholic solvents, water can be another

Be part of it.

In a preferred embodiment, the preparations to be used contain hydrophilic surfactants. The hydrophilic surfactants are preferably selected from the group of alkylglucosides, acyl lactylates, betaines and cocoamphoacetates. As emulsifiers, for example, the known W / O and O / W emulsifiers can be used. It is advantageous to use other conventional co-emulsifiers in the preferred ΟΛ V emulsions. For example, O / W emulsifiers are selected as co-emulsifiers, principally from the group of substances with HLB values of 11-16, very particularly advantageously with HLB values of 14.5-15.5, provided that the O / W Emulsifiers have saturated radicals R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value may be those of

Emulsifiers also lower or above.

It is advantageous to include the fatty alcohol ethoxylates from the group of

ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols

(Cetearyl alcohols).

It is also advantageous to choose the fatty acid ethoxylates from the following group:

 Polyethylene glycol (20) stearate, polyethylene glycol (21) stearate,

 Polyethylene glycol (22) stearate, polyethylene glycol (23) stearate,

 Polyethylene glycol (24) stearate, polyethylene glycol (25) stearate,

 Polyethylene glycol (12) isostearate, polyethylene glycol (13) isostearate,

 Polyethylene glycol (14) isostearate, polyethylene glycol (15) isostearate,

 Polyethylene glycol (16) isostearate, polyethylene glycol (17) isostearate,

 Polyethylene glycol (18) isostearate, polyethylene glycol (19) isostearate,

 Polyethylene glycol (20) isostearate, polyethylene glycol (21) isostearate,

 Polyethylene glycol (22) isostearate, polyethylene glycol (23) isostearate,

 Polyethylene glycol (24) isostearate, polyethylene glycol (25) isostearate,

 Polyethylene glycol (12) oleate, polyethylene glycol (13) oleate,

 Polyethylene glycol (14) oleate, polyethylene glycol (15) oleate,

 Polyethylene glycol (16) oleate, polyethylene glycol (17) oleate,

Polyethylene glycol (18) oleate, polyethylene glycol (19) oleate, Polyethylene glycol (20) oleate.

As the ethoxylated alkyl ether carboxylic acid or its salt, the sodium laureth-11-carboxylate can be advantageously used. As the alkyl ether sulfate, sodium LauretM 4 sulfate can be advantageously used. As the ethoxylated cholesterol derivative, polyethylene glycol (30) cholesteryl ether can be advantageously used. Also polyethylene glycol (25) soybean oil has been proven. As ethoxylated triglycerides, the polyethylene glycol (60) Evening Primrose Glycerides can advantageously be used (Evening Primrose = evening primrose).

It is furthermore advantageous to use the polyethylene glycol glycerol fatty acid esters from the group of polyethylene glycol (20) glyceryl dilaurate,

Polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate,

 Polyethylene glycol (6) glycerylcaprat / cprinat,

 Polyethylene glycol (20) glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene glycol (18) glyceryl oleate (cocoate). It is also beneficial to have the sorbitan esters from the group

 Polyethylene glycol (20) sorbitan monolaurate,

 Polyethylene glycol (20) sorbitan monostearate,

 Polyethylene glycol (20) sorbitan monoisostearate,

 Polyethylene glycol (20) sorbitan monopalmitate,

 Polyethylene glycol (20) to choose sorbitan monooleate.

As optional, but according to the invention optionally advantageous W / O emulsifiers can be used:

 Fatty alcohols having 8 to 30 carbon atoms, onoglycerol esters of saturated and / or unsaturated, branched and / or unbranched

Alkanecarboxylic acids of a chain length of 8 to 24, in particular 12-18 C atoms, diglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 12-18 C ^~ > atoms, monoglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols

Chain length of 8 to 24, in particular 12-18 C-atoms, diglycerol ethers of saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 2-8 carbon atoms and sorbitan esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 12-18, carbon atoms.

Particularly advantageous W / O emulsifiers are glyceryl monostearate, glyceryl monoisostearate, glyceryl monomyristate, glyceryl monooleate,

Diglyceryl monostearate, diglyceryl monoisostearate,

 Propylene glycol monostearate, propylene glycol monoisostearate,

Propylene glycol monocaprylate, propylene glycol monolaurate,

Sorbitan monoisostearate, sorbitan monolaurate, sorbitan monocaprylate, sorbitan monoisooleate, sucrose distearate, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (steareth-2),

Glyceryl monolaurate, glyceryl monocaprinate, glyceryl monocaprylate or PEG-30 dipolyhydroxystearate. The preparation may contain cosmetic adjuvants which are commonly used in this type of preparations, e.g.

Thickeners, emollients, moisturizers,

surfactants, emulsifiers, preservatives, antifoaming agents, perfumes, waxes, lanolin, propellants, dyes and / or pigments, and other ingredients commonly used in cosmetics. It is possible to use as dispersion or solubilizing agent an oil, wax or other fatty substance, a low monoalcohol or a low polyol or mixtures thereof. Particularly preferred monoalcohols or polyols include ethanol, i-propanol, propylene glycol, glycerine and sorbitol.

Even without further statements, it is assumed that a person skilled in the art can make the most of the above description. The preferred embodiments and examples are therefore merely illustrative and in no way limiting in any way

 To understand the revelation. The complete disclosure of all applications and publications cited above and below are incorporated by reference into this application.

Examples:

Example 1: Ethanol extract from Tradescantia virginiana

 35.3 g fresh Tradescantia virginiana leaves (plant commercially available) are extracted at 78 ° C with 250 ml of ethanol for 60 min under reflux. After removal of the solvent in a rotary evaporator, the extract obtained is taken up in 100 ml of water and for further purification of lipophilic substances and chlorophyll against heptane

shaken. After discarding the heptane phase of the

Water residue evaporated. This gives 730 mg of substance.

Example 2: Water extract from Tradescantia virginiana

43.6 g of fresh Tradescantia virginiana leaves are extracted at 100 ° C with 250 ml of water for 60 min. After removal of the solvent in

Rotary evaporator gives 490 mg of the extract. Example 3 Stimulation of Melanin Synthesis with Ethanol Extracts from Example 1

 Carrying out the B16 V mouse melanoma cell test:

B16V mouse melanoma cells (manufacturer: DSMZ, article number: ACC370) are mixed in RPMI medium (Invitrogen, article no .: 31870), which additionally contains 10% FBS (fetal bovine serum; Invitrogen, article no: 10499044 ), 2 mM L-glutamine (Invitrogen, item no: 25030) and 1 mM sodium pyruvate (Invitrogen, item no: 11360) are added and incubated for 72 h at 37 ° C and 5% C0 ₂ . The medium is separated and the cells are washed once with 10 ml DPBS (Dulbecco's Phosphate-Buffered Salines, Invitrogen, Item No. 14190) and the medium is then aspirated. 1 ml HyQtase-Cell Detachment Solution (Hyclone, article number SV30030.01) is added to the cells. The bottle is swiveled several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% CO 2. The cells are taken up in the modified RPMI medium (see above) and the number of cells determined. For this, the cells are stained with trypan blue and counted in a Neubauer counting chamber. Subsequently, the cells are seeded again in the modified RPMI medium (see above) in a defined cell number of 80,000 cells per well (6-well Clear Plate, TCT, PS (Nunc)).

The cells are incubated for 24 h at 37 ° C. and 5% CO 2, after which the medium is removed. Subsequently, 1980pL of the substance dilution

added. For this dilution of the substance, the ethanol extract from Example 1 is dissolved in DMSO and then filtered through a sterile filter (0.2 μm, Millipore, Article No. SLLG013SL). The solution is then diluted with the modified RPMI medium (see above, but in this case the FBS content is only 5%) such that the final concentration of the extract is 0.1 mg / ml, 0.05 mg / ml and 0, respectively , 01 mg / ml. Then, 20 L of an alpha-MSH solution (alpha-melanocyte stimulating hormone, DMSO, Sigma, item no: D2650) is added so that the alpha MSH concentration in the well is 10 ^~ 8M. The mixture is then incubated again for 24 h at 37 ° C and 5% CO2. The process described in this section is repeated twice more.

After the last incubation period, the medium is aspirated and the cells are washed with 1000 μl DPBS (Invitrogen, Item No. 14190). The medium is sucked off again. It will be 250pL HyQtase Cell

Detachment Solution (Hyclone, Item No. SV30030.01) is added to the cells. The 6-well plate is pivoted several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% C0 ₂ . The cells are taken up in 1.5mL DPBS (Invitrogen, Item No. 14190) and transferred to a cup (SARSTEDT, Ref. 72.692.005). Subsequently, the cell number is determined. For this, the cells are stained with trypan blue and counted in a Neubauer counting chamber. Centrifuge the cells at 3500g for 1min. The obtained pellets are photographed and

then the supernatant is sucked off. The pellets are dissolved in 1 ml of 1 N NaOH for 1 h at 80 ° C. and then cooled to RT. Then 200pL (as a quadruple determination) are pipetted four times per cup into a 96 well plate (VWR, article no. 4100636981) and the absorption at 405 nm wavelength determined (Satire, Tecan). By means of a calibration line, the content of melanin can be determined

As a comparison, a sample without extract but with 0.1% DMSO or with 0.1% DMSO and alpha-MSH (concentration in the well at 10 ^-8 M) is used in parallel, whereas IBMX (3-isobutyl-1 methylxantine (Calbiochem, No. 410957).

Results (Table 1): The extract of Tradescantia virginiana from Example 1 causes a

Increasing the level of melanin in both the non-stimulated and in the α-MSH tanning-stimulated melanocytes. This means that the extracts according to the invention can even stimulate cells which have already been stimulated by α-MSH, in addition to further synthesizing melanin.

 The extract also has an inverse concentration dependence with respect to its skin tanning action. He is already effective in very low concentrations.

Table 1: Content of melanin per cell:

Example 4: Skin lightening effect of water extracts

Tradescantia virginiana:

B16V mouse melanoma cells (manufacturer: DSMZ, article number: ACC370) are mixed in RPMI medium (Invitrogen, article no .: 31870), which additionally contains 10% FBS (fetal bovine serum; Invitrogen, article no: 10499044 ), 2 mM L-glutamine (Invitrogen, item no: 25030) and 1 mM sodium pyruvate (Invitrogen, item no: 11360) are added and incubated for 72 h at 37 ° C and 5% C0 ₂ . The medium is separated off and the cells are washed once with 10 ml of DPBS (Dulbecco's Phosphate-Buffered Salines, Invitrogen, Article No. 14190) and the medium is subsequently aspirated off. 1 mL of HyQtase-Cell Detachment Solution (Hyclone, Article no. SV30030.01) on the cells. The bottle is swiveled several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% C0 ₂ . The cells are taken up in the modified RPMI medium (see above) and the number of cells determined. For this, the cells are stained with trypan blue and counted in a Neubauer counting chamber. Subsequently, the cells are seeded again in the modified RPMI medium (see above) in a defined cell number of 80,000 cells per well (6-well Clear Plate, TCT, PS (Nunc)).

The cells are incubated for 24 h at 37 ° C. and 5% CO 2, after which the medium is removed. Then 1980μΙ_ of the substance dilution

added. For this dilution of the substance, the water extract from Example 2 is dissolved in water and then filtered through a sterile filter (0.2 μm, Millipore, Article No. SLLG013SL). The solution is then diluted with the modified RPMI medium (see above, but in this case the FBS content is only 5%) such that the final concentration of the extract is 0.1 mg / ml, 0.05 mg / ml and 0, respectively , 01 mg / ml. Then 20 μΙ_ of an alpha-MSH solution (alpha-melanocyte stimulating hormone, DMSO, Sigma, Article No.: D2650) is added such that the alpha-MSH concentration in the well is 10 ^-8 M. Subsequently, the mixture is again incubated at 37 ° for 24 h ° C and 5% CO2 The procedure described in this section is repeated twice more.

After the last incubation period, the medium is aspirated and the cells are washed with 1000 μl DPBS (Invitrogen, Item No. 14 90). The medium is sucked off again. It will be 250pL HyQtase Cell

Detachment Solution (Hyclone, Item No. SV30030.01) is added to the cells. The 6-well plate is pivoted several times and the HyQtase- Cell Detachment Solution is then removed by suction. Then the cells are incubated for 5 min in the incubator at 37 ° C and 5% C0 ₂ . The Cells are picked up in 1.5mL DPBS (Invitrogen, Item No. 14190) and transferred to a cup (SARSTEDT, Ref. 72.692.005). Subsequently, the cell number is determined. For this, the cells are stained with trypan blue and counted in a Neubauer counting chamber. Centrifuge the cells at 3500g for 1min. The obtained pellets are photographed and

then the supernatant is sucked off. The pellets are dissolved in 1 mL of 1 N NaOH for 1 h at 80 ° C and then cooled to RT. Then 200μΙ_ (as quadruple determination) are pipetted four times per cup into a 96 well plate (VWR, article no. 4100636981) and the absorption at 405 nm wavelength determined (Safire, Tecan). By means of a calibration line, the content of melanin can be determined

As a comparison, one sample is used in parallel without extract but with 0.1%

Water or with 0.1% water and alpha-MSH (concentration in the well at 10 ^-8 M) is used as a positive control hydroquinone (5 μΜ).

Results:

 The water extract from Tradescantia virginiana from Example 2 causes a reduction of the melanin content in the by α-MSH for browning

stimulated melanocytes.

Table 2: Melanin content per cell:

Example 5: O / W emulsions for skin lightening or

Tanning reinforcement, data in% by weight

Ingredients 1-1 1-2 1-3 1-4 1-5

Titanium dioxide 2 5

 Methylene bis

Benztriazolyltetramethylbuty

 Iphenol

 Tradesantia virginiana 0.5 0.25 0.1 0.25 0.1

Extract of Example 1 or

 2

 4-methylbenzylidene camphor 2 3 4

BMDBM 1 3 3 3

Stearyl alcohol (and) 3 3 3 3 3

Steareth-7 (and) steareth

10

 Glyceryl stearate (and) 3 3 3 3 3

Ceteth-20

 Glyceryl stearate 3 3 3 3 3

Microwax 1 1 1 1 1

Cetearyl octanoate 11, 5, 11, 5, 11, 5, 11, 5, 11, 5

Caprylic / Capric triglyceride 6 6 6 6 6

Oleyl oleate 6 6 6 6 6

Propylene glycol 4 4 4 4 4

Propylparaben 0.05 0.05 0.05 0.05 0.05

Methyl paraben 0.15 0.15 0.15 0.15 0.15

Tromethamine 1, 8

Water Ad 100 Ad 100 Ad 100 Ad 100 Ad 100 Example 6: O / W formulation

 Production method:

 First, phase A is heated to 75 ° C and phase B to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A and stirred until a homogeneous mixture is formed.

Sources:

 (1) Sasol Germany GmbH (2) Cognis GmbH (3) BASF AG

(4) Degussa-Goldschmidt AG (5) Merck KGaA / Rona® Example 7: O / W Formulation

 Production method:

 First, phase A is heated to 75 ° C and phase B to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A and stirred until a homogeneous mixture is formed.

Sources:

 (1) Sasol Germany GmbH (2) Cognis GmbH (3) BASF AG

(4) Degussa-Goldschmidt AG (5) Merck KGaA / Rona®

Example 8: O / W Formulation

Production method:

First, phases A and B are heated to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A and homogenized. It is then cooled and the phase C at 40 ° C was added. Sources:

 (1) Degussa-Goldschmidt AG, (2) Cognis GmbH, (3) BASF AG, (4) Sasol Germany GmbH, (5) Merck KGaA / Rona®, (6) Dow Corning, (7) Kuhs GmbH & Co. KG

Example 9: W / O formulation

Production method:

 First, phase B is dissolved and then it is given to phase A. The pH is adjusted to pH = 6.0 with sodium hydroxide solution or citric acid.

Sources:

(1) Dow Coming (2) Merck KGaA / Rona® Example 10: OW Anti-aqinq cream with UV A / B protection

 Production method:

 First, phases A and B are mixed separately and heated to 80 ° C. Thereafter, phase B is slowly added with stirring to phase A. It is homogenized cooled to room temperature.

Reference documents: (1) Merck KGaA / Rona®, (2) Degussa-Goldschmidt AG, (3) Cognis GmbH, (4) BASF AG, (5) Sasol Germany GmbH, (6)

Claims

 claims

1. Extract of plant parts of Tradescantia virginiana.

A process for producing an extract according to claim 1, comprising the steps of a) extracting the plant parts of Tradescantia virginiana using a solvent and optionally b) removing the

 Solvent.

A method according to claim 2, characterized in that the

 Solvent is selected from water, organic solvents or mixtures thereof.

A method according to claim 2 or 3, characterized in that in a step c) the extract obtained is concentrated and / or dried.

Use of an extract from plant parts of Tradescantia virginiana according to claim 1 in cosmetic or dermatological preparations.

6. Use according to claim 5 for lightening the skin.

Use according to claim 6 for the inhibition of melanin synthesis, for the prophylaxis, treatment and / or follow-up of

 Pigment disorders of the skin.

Use according to one or more of claims 5 to 7, characterized in that it is a water extract.

9. Use according to claim 5 as a self-tanning agent.

10. Use according to claim 9 for increasing melanin synthesis, improving melanin transport and / or improving the distribution of melanin in suprabasal layers.

11.Use according to one or more of claims 5, 9 and 10, characterized in that it is an ethanol extract. 2. Preparation containing an extract of plant parts of

 Tradescantia virginiana according to claim 1.

13. A preparation according to claim 12, characterized in that it is a cosmetic or dermatological preparation.

14. A preparation according to claim 12 or 13, characterized in that the preparation 0.01 to 99 wt.% Of the extract of plant parts of Tradescantia virginiana, based on the total weight of

 Preparation containing.

15. A process for preparing a preparation according to one or more of claims 12 to 14, characterized in that the extract of plant parts of Tradescantia virginiana is mixed with a suitable carrier for topical applications.